Durgical
EN
Open the app

Neonatal herpes simplex

Herpes caught at birth can reach a newborn's brain and organs within days. It often shows no blisters, so aciclovir is started on suspicion.

Updated

What it is

Infection of a newborn with herpes simplex virus type 1 or 2, acquired mostly during birth. It takes three forms: skin, eye and mouth (SEM) disease, central nervous system (CNS) disease and disseminated disease, and usually appears in the first weeks of life rather than at birth.

Who gets it

Rare but severe: WHO estimates about 10 cases per 100,000 births worldwide. About 85% of infections are acquired around delivery, about 10% after birth (often HSV-1 from a relative's or carer's cold sore) and about 5% in the womb. Most mothers of affected babies have no known history of genital herpes.

Causes

  • HSV-2 or HSV-1 from the mother's genital tract during birth, usually from unrecognised or asymptomatic shedding
  • Postnatal spread from anyone with a cold sore or oral shedding (usually HSV-1)
  • Rarely, intrauterine infection, which presents at or shortly after birth

Risk factors

  • Maternal first (primary) genital infection near delivery: transmission risk up to about 60%, against under 2% with a recurrence
  • Invasive monitoring and instrumental delivery: fetal scalp electrodes, scalp sampling, forceps or vacuum
  • Early or prolonged rupture of the membranes
  • Prematurity, especially before about 32 weeks (less maternal antibody has crossed the placenta)
  • Contact with people who have cold sores

Pathophysiology

Virus in the birth canal reaches the baby's skin, conjunctivae and mouth → it replicates in epithelium, forming clustered vesicles (SEM disease) → without treatment it can travel along nerves to the brain (CNS disease: encephalitis) or enter the bloodstream (disseminated disease) → in disseminated disease the virus destroys liver cells (hepatitis, liver failure), inflames the lungs and consumes clotting factors (disseminated intravascular coagulation) → maternal antibodies acquired before birth limit spread, so a baby whose mother had a primary infection late in pregnancy, or who is very premature, is least protected.

Classification

  • Skin, eye and mouth (SEM) disease: about 45% of cases
  • CNS disease, with or without skin lesions: about 30%
  • Disseminated disease (liver, lungs, clotting, often brain too): about 25%
  • Intrauterine (congenital) infection: rare (under 5%), with skin lesions or scars, brain damage or chorioretinitis, present at or shortly after birth

Symptoms and signs

  • SEM: clustered vesicles on a red base, conjunctivitis or keratitis, mouth ulcers
  • CNS: lethargy, irritability, poor feeding, temperature instability, a bulging fontanelle and focal or generalised seizures
  • Disseminated: a sepsis-like picture with poor feeding, breathing difficulty, jaundice, a large liver, bleeding and shock
  • Vesicles may never appear: in about one in six SEM cases, about a third of CNS cases and about four in ten disseminated cases

Diagnosis

Clinical
Suspected in any unwell infant up to about six weeks old with vesicles, seizures, a sepsis picture without a bacterial cause, hepatitis or coagulopathy, whether or not the mother has a history of herpes. SEM and disseminated disease usually present around 10–12 days of life, CNS disease around 16–19 days; most cases appear in the first four weeks.
Tests
PCR of swabs from vesicles and from the conjunctivae, mouth and nasopharynx; blood HSV PCR; cerebrospinal fluid HSV PCR in every case (a normal CSF cell count does not exclude CNS disease); liver enzymes, blood count and clotting. Infant serology does not help. Surface swabs from an exposed baby are best taken at least 24 hours after birth so that maternal virus is not mistaken for infection.
Imaging
Brain MRI to show the extent of CNS involvement; chest radiography for pneumonitis in disseminated disease; EEG when seizures are suspected.

Differential diagnosis

Three forms of neonatal herpes, and the look-alike

FormTypical onsetWhat you seeOutcome with aciclovir
Skin, eye and mouth (SEM)Around 10–12 daysClustered vesicles, conjunctivitis or keratitis, mouth ulcers; about one in six has no vesiclesSurvival is the rule; treatment stops spread to the brain and organs
CNS diseaseAround 16–19 days (second to third week)Lethargy, poor feeding, bulging fontanelle, seizures; a third have no vesiclesAbout one in seven dies within a year; most survivors have neurological sequelae
Disseminated diseaseAround 10–12 daysSepsis picture, hepatitis, coagulopathy, pneumonitis; about four in ten have no vesiclesHighest mortality, close to three in ten within a year
Bacterial neonatal sepsisFirst 72 hours (early onset) or laterFever or instability, positive blood or CSF culturesImproves on antibiotics; negative cultures and no improvement point back to HSV

Goal of treatment

Start intravenous aciclovir as soon as the disease is suspected, before results return, to stop spread to the brain and organs; then prevent recurrences, follow development, sight and hearing, and prevent transmission at birth through delivery planning.

Treatment

Acute
Intravenous aciclovir for every known or suspected case, started on suspicion and not delayed for PCR results; the course is longer for CNS and disseminated disease than for SEM disease, as the guideline sets. Oral aciclovir is never used for acute treatment, because it does not reach adequate levels.
Follow-up
Supportive neonatal intensive care for seizures, respiratory failure, liver failure and coagulopathy; repeat CSF PCR at the end of treatment in CNS disease, as the guideline sets.
Medical
Oral aciclovir suppression after the intravenous course, which improves neurodevelopment after CNS disease and reduces skin recurrences; the evidence is weaker after SEM or disseminated disease.
Conservative
Delivery planning: at the onset of labour ask about genital symptoms and prodrome and examine for lesions. Lesions or prodrome at term, whether primary or recurrent, lead to caesarean delivery, which lowers but does not abolish the risk; women without lesions or prodrome deliver vaginally. Scalp electrodes and instrumental delivery are avoided when there is a risk.
Medical
Women with recurrent genital herpes are offered suppressive oral antiviral therapy from late pregnancy, as the guideline sets, which reduces lesions at term and caesareans. A first episode in the second half of pregnancy is managed with maternal-fetal medicine and infectious diseases specialists.
Rehabilitation
Long-term follow-up of neurodevelopment, vision and hearing, with early intervention when deficits appear.

Complications

  • Death, mainly from disseminated disease (liver failure, disseminated intravascular coagulation, pneumonitis)
  • Microcephaly, epilepsy, cerebral palsy and developmental delay after CNS disease
  • Blindness from keratitis, chorioretinitis or brain injury
  • Recurrent skin lesions in the first months, and progression of untreated SEM disease to CNS or disseminated disease

Common traps

  • No vesicles means no neonatal herpes: many babies with CNS or disseminated disease never have vesicles, so think of HSV in any septic, seizing or hepatitic baby under six weeks
  • Neonatal herpes is a congenital infection present at birth: most is caught during delivery and appears in the second or third week, after a well-looking first days
  • A known history of maternal genital herpes is the biggest risk: a first infection near term is far more dangerous than a recurrence, and most mothers of affected babies never knew they were infected
  • A caesarean section removes the risk: it lowers transmission but does not abolish it, especially after the membranes have ruptured
  • A normal CSF cell count rules out CNS herpes: HSV PCR of the cerebrospinal fluid is the test, and treatment starts before it returns

Prognosis

Before antivirals about 85% of disseminated and about half of CNS cases died. With intravenous aciclovir one-year mortality is about 29% for disseminated and 14% for CNS disease, and about 70% of CNS survivors have neurological complications. Treated SEM disease carries little or no long-term harm. Early treatment improves every form.

Prevention

  • Ask every pregnant woman and her partner about genital herpes, and plan delivery for women at risk
  • Suppressive antiviral therapy from late pregnancy for women with recurrent genital herpes
  • Anyone with a cold sore avoids kissing the baby, covers the lesion and washes hands
  • Follow exposed newborns closely with a paediatric infectious diseases specialist

Test yourself

Think of the answer, then tap the question to see it.

Why is a primary maternal genital HSV infection near term much more dangerous for the baby than a recurrence?

After a recurrence the mother already has antibodies that cross the placenta and protect the baby; a first infection near term gives no such protection, so transmission rises from under 2% to as much as 60%.

What are the three forms of neonatal herpes, and when does each usually present?

Skin, eye and mouth disease and disseminated disease, around 10–12 days of life; CNS disease, around 16–19 days. Most cases appear within the first four weeks.

A 9-day-old is lethargic with a high ALT and oozing from puncture sites; cultures are negative at 24 hours and there are no vesicles. What next?

Suspect disseminated neonatal herpes: start intravenous aciclovir at once, send blood, CSF and surface swab HSV PCR, and support clotting and liver function. Absent vesicles do not exclude it.

A woman with recurrent genital herpes has a typical lesion at the onset of labour. How is the birth managed, and what are its limits?

Caesarean delivery is recommended because a lesion at labour means active shedding. It lowers transmission but does not abolish it, so the baby is still followed closely.

Why does a baby with CNS herpes receive oral aciclovir after the intravenous course?

Suppression after CNS disease improves neurodevelopmental outcome and reduces skin recurrences; it is not used for acute treatment because oral levels are too low.

Add to my cards (5)

Why it happens

In pediatrics

Connections

Educational information, not medical advice. For any symptom, see a health professional.

Sources: Genital Herpes - STI Treatment Guidelines (US Centers for Disease Control and Prevention (CDC), 2021); Prevention and management of neonatal herpes simplex virus infections (Canadian Paediatric Society, 2025); Neonatal Herpes Simplex Infection (Clinical Microbiology Reviews (PMC), 2004); Herpes simplex virus (World Health Organization, 2025).

← All conditions

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.